Canadian Sec - Delayed Quote • CAD Sona Nanotech Inc. (SONA.CN) Follow Compare 0.2700 +0.0150 +(5.88%) At close: 3:56:11 PM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for SONA.CN 1D 5D 8.00% 1M 5.88% 3M -3.57% 6M -10.00% YTD 8.00% 1Y -3.57% 5Y 92.86% All -58.46% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: SONA.CN View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update Sona Nanotech Issued Patent and Appoints New Board Member Sona Nanotech Grants Options Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds Sona Nanotech Closes Private Placement Financing to Raise $1,500,000 in Gross Proceeds and Announces Additional Financing Sona Nanotech to Arrange Private Placement Financing Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent Related Tickers SZLS.TO StageZero Life Sciences Ltd. 0.0400 0.00% MEDVF Medivolve Inc. 0.0070 0.00% AWH Aspira Women's Health Inc. 0.5769 -6.70% AVCR.V Avricore Health Inc. 0.0650 0.00% PRPO Precipio, Inc. 6.06 +3.24% IZO.CN Izotropic Corporation 0.1550 -6.06% APDN Applied DNA Sciences, Inc. 0.1825 -5.64%